ProfileGDS5678 / 1426109_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 25% 26% 25% 27% 29% 26% 25% 26% 26% 27% 26% 26% 26% 26% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6180725
GSM967853U87-EV human glioblastoma xenograft - Control 22.5984226
GSM967854U87-EV human glioblastoma xenograft - Control 32.583225
GSM967855U87-EV human glioblastoma xenograft - Control 42.5743127
GSM967856U87-EV human glioblastoma xenograft - Control 52.6043729
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6573426
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6187625
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.592126
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5723326
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.613627
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5906526
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5753126
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5914426
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5973326